Bone Biologics Corp

For the period ended Jun 30, 2026. Filed Aug 14, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 14, 2026

BBLG$0.34+3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Condensed Consolidated Statements of Stockholders’ Equity

Condensed Consolidated Statement of Stockholders’ Equity

For the Six Months ended June 30, 2026

(unaudited)

Common Stock · Additional Paid-in · Accumulated · Total Stockholders’
	Shares	Amount	Capital	Equity	Equity
Balance at December 31, 2025	1,795,260	$1,795	$93,506,122	$(88,130,369)	$5,377,548
Fair value of vested stock options	-	-	23,505	-	23,505
Options issued to settle accrued bonus	-	-	34,854	-	34,854
Net Loss	-	-	-	(765,988)	(765,988)
Balance at March 31, 2026	1,795,260	1,795	93,564,481	(88,896,357)	4,669,919
Fair value of vested stock options	-	-	8,253	-	8,253
Issuance of common shares from ATM, net of costs of $2,090	15,120	15	20,165	-	20,180
Net Loss	-	-	-	(773,702)	(773,702)
Balance at June 30, 2026	1,810,380	$1,810	$93,592,899	$(89,670,059)	$3,924,650

Condensed Consolidated Statement of Stockholders’ Equity

For the Six Months ended June 30, 2025

(unaudited)

Common Stock · Additional Paid-in · Accumulated · Total Stockholders’
	Shares	Amount	Capital	Equity	Equity
Balance at December 31, 2024	492,417	$492	$88,504,543	$(85,021,378)	$3,483,657
Fair value of vested stock options	-	-	50,605	-	50,605
Options issued to settle accrued bonus	-	-	46,183	-	46,183
Issuance of common shares from ATM, net of costs of $13,029	52,843	53	347,496	-	347,549
Net Loss	-	-	-	(1,017,092)	(1,017,092)
Balance at March 31, 2025	545,260	545	88,948,827	(86,038,470)	2,910,902
Fair value of vested stock options	-	-	72,899	-	72,899
Proceeds from sale of common stock and warrants in public offering, net of offering costs of $647,208	793,750	794	4,351,998	-	4,352,792
Exercise of pre-funded warrants	346,250	346	(346)	-	-
Net Loss	-	-	-	(740,519)	(740,519)
Balance at June 30, 2025	1,685,260	$1,685	$93,373,378	$(86,778,989)	$6,596,074

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.